Ascidian Therapeutics has entered a research partnership and licensing agreement with Roche to discover and develop RNA exon editing therapies to treat neurological diseases. The partnership will ...

June 18 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab will team up with privately held biotech Ascidian Therapeutics to develop gene therapies targeting difficult to treat neurological ...

Inspired by ocean “sea squirts,” Ascidian Therapeutics is floating to the surface with $50 million in series A treasure to fund its ambitions to rewrite RNA for therapeutic benefit. The company, ...

Ascidian Therapeutics, a company developing RNA rewriting (or RNA exon editing) technology, announced a research collaboration and licensing agreement with Roche for the discovery and development of ...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray A. Abramson, MD, MPH, ...

From left to right: Ascidian Therapeutics' Chief Financial & Business Officer Dan Rosan, Senior Vice President and Head of Research Robert Bell, and Chief Medical Officer Jay Barth. Biotechnology ...

The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics. Ascidian Therapeutics, a biotechnology company developing treatments by ...

The public markets remain volatile but private financings continue to remain a viable way for life sciences companies to find the capital they need to support their work. The funding rounds this week ...

Roche and Ascidian Therapeutics have partnered to develop RNA exon editing therapies for neurological diseases, with the deal worth over $1.8bn. The research collaboration and licensing agreement ...

Forge’s FUEL™ platform and cGMP manufacturing services support the production of AAV for Ascidian’s ACDN-01, the most advanced genetic therapy targeting the underlying cause of Stargardt disease ...

Competition is heating up among biotech startups building technologies that improve or expand upon what gene editing can do. While most of these firms are devising therapies that permanently modify ...